8(top 5%)
papers
316(top 5%)
citations
4(top 5%)
h-index
7(top 5%)
g-index
8
all documents
327
doc citations
165
citing journals

Top Articles

#TitleJournalYearCitations
1A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignanciesBlood2016231
2Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association reportBlood201773
3Randomized phase III study comparing an early PET driven treatment de-escalation to a not PET-monitored strategy in patients with advanced stages Hodgkin lymphoma: Final analysis of the AHL2011 LYSA study.Journal of Clinical Oncology201812
4THE RISK OF TRANSFORMATION OF FOLLICULAR LYMPHOMA “TRANSFORMED” BY RITUXIMAB: THE ARISTOTLE STUDY PROMOTED BY THE EUROPEAN LYMPHOMA INSTITUTEHematological Oncology20178
5First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin’s lymphomaBone Marrow Transplantation20171
6PRELIMINARY RESULTS OF A PHASE 1B STUDY OF TIRABRUTINIB (GS‐4059/ONO‐4059) IN COMBINATION WITH ENTOSPLETINIB IN PATIENTS WITH B‐CELL MALIGNANCIESHematological Oncology20171
7Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of GS-4059 in Combination with Idelalisib in Subjects with B-Cell MalignanciesBlood20161
8Preliminary results of a phase Ib study of GS-4059 in combination with entospletinib in patients with B-cell malignancies.Journal of Clinical Oncology20170